Mumbai: The Maharashtra Food and Drug Administration (FDA) has seized nutraceutical and health supplement products worth Rs 1.39 crore from 17 establishments across the state during a statewide enforcement drive targeting products containing ingredients rejected by the country's food safety regulator.

One of the major seizures was carried out at a warehouse in Bhiwandi, Thane district, where FDA officials confiscated health supplement stock valued at Rs 47.65 lakh. The seizure represented one of the highest amounts recovered from a single establishment during the operation.

The statewide crackdown was conducted simultaneously on November 13 and covered manufacturers, marketers, distributors and retailers dealing in health supplements and foods for special dietary use. During inspections, officials identified products containing magnesium acetyl taurate and nicotinamide mononucleotide (NMN), two ingredients for which product approval applications had been rejected by the Food Safety and Standards Authority of India (FSSAI).

Also Read: 13 Indian Forensic Medicine doctors, scientists get recognised in Stanford University Top 2% Scientists

The major seizure in Bhiwandi was conducted at the warehouse of Kanchan Pharma Pvt Ltd, located at Bhumi World Industrial Park, Pimplas. The company was also found to be connected with the enforcement action at other locations, including Pune and Nagpur, as part of the wider statewide operation.

According to the FDA, products worth approximately Rs 1.39 crore were seized from 17 establishments during the crackdown. Four nutraceutical products were specifically identified during the inspection drive: Rejuvance, Altibrain-S, Magladense and EQOQ.

The FDA press release stated that these formulations contained either magnesium acetyl taurate or nicotinamide mononucleotide, or both ingredients, along with other substances. The products came under regulatory scrutiny because the approval applications for these ingredients had been rejected by FSSAI.

The enforcement action followed directions issued by FSSAI on June 3 regarding the product approval applications submitted for the two ingredients. FDA officials stated that certain manufacturers had produced these health supplements without obtaining the mandatory regulatory approvals. Additionally, marketers were found selling the products without including the relevant food category in their respective licences.

The FDA highlighted that the manufacture and marketing of such products without complying with the applicable food safety and licensing requirements constituted a violation of regulatory provisions. The operation was aimed at preventing the sale and distribution of health supplements containing ingredients that had not received the necessary regulatory approval.

The nutraceutical enforcement drive formed part of a broader statewide food safety initiative undertaken by the Maharashtra FDA under its ‘Safe Food, Safe Maharashtra’ campaign. The campaign focuses on strengthening food safety surveillance, monitoring regulated products and taking enforcement action against establishments involved in the manufacture, storage and sale of non-compliant food products.

Apart from the action against nutraceutical manufacturers and distributors, the FDA also initiated enforcement measures against seven establishments and vehicles involved in the storage and sale of prohibited products, including gutka and scented pan masala. During this operation, officials seized prohibited stock and also confiscated a vehicle associated with the activities.

In a separate action in Mumbai, the FDA seized prohibited food articles worth Rs 31,149 from six pan shops. The inspections covered establishments located in Dahisar, Dharavi, Goregaon and Antop Hill, reports The Times of India.

Also Read: FSSAI Proposes Red Warning Labels for Packaged Foods High in Sugar, Salt, Fat

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .